INSP vs UFPT
INSP: Inspire Medical Systems provides a unique, neurostimulation-based alternative therapy for obstructive sleep apnea patients who struggle with traditional PAP machines. UFPT: A specialized contract manufacturer producing custom single-use and single-patient medical devices for major OEMs across minimally invasive surgery, wound care, orthopedics, and biopharma applications.
Side-by-side fundamentals
| Metric | INSP | UFPT | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $50.21 | $254.78 | |
| Market cap as of 2026-08-03 | $1.4B | $2.0B | |
| P/E as of 2026-08-03 | 11.21 | 28.98 | INSP lower |
| PEG as of 2026-08-03 | 0.11 | 3.66 | INSP lower |
| Net margin as of 2026-08-03 | +14.3% | +11.3% | INSP higher |
| Gross margin as of 2026-08-03 | +85.8% | +28.4% | INSP higher |
| Operating margin as of 2026-08-03 | +5.2% | +15.2% | UFPT higher |
| ROE as of 2026-08-03 | +18.0% | +16.6% | INSP higher |
| ROA as of 2026-08-03 | +15.3% | +10.5% | INSP higher |
| Debt / equity as of 2026-08-03 | 0.00 | 0.31 | INSP lower |
| Revenue growth (YoY) as of 2026-08-03 | +8.9% | +11.2% | UFPT higher |
| Revenue CAGR (3y) SEC XBRL | +30.8% | +22.7% | INSP higher |
| Beta as of 2026-08-03 | 0.93 | 1.02 | |
| 1-year return as of 2026-07-31 close | -59.7% | +12.5% | UFPT higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.